| Year |
Citation |
Score |
| 2016 |
Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS, Svarovskaia E, Knox SJ, Loustaud-Ratti V, Asselah T. Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection. Hepatology (Baltimore, Md.). PMID 27351341 DOI: 10.1002/Hep.28706 |
0.551 |
|
| 2016 |
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir. Gastroenterology. PMID 27296509 DOI: 10.1053/J.Gastro.2016.06.002 |
0.516 |
|
| 2016 |
Cooper C, Naggie S, Saag M, Yang JC, Stamm LM, Dvory-Sobol H, Han L, Pang PS, McHutchison JG, Dieterich D, Sulkowski M. Successful Retreatment of HCV in Patients Coinfected with HIV Who Failed 12 Weeks of Ledipasvir/Sofosbuvir. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 27225242 DOI: 10.1093/Cid/Ciw349 |
0.477 |
|
| 2016 |
Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, Yoon SK, Yim HJ, Tak WY, Han SY, Yang JC, Mo H, Garrison KL, Gao B, ... ... Pang PS, et al. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatology International. PMID 27198664 DOI: 10.1007/S12072-016-9726-5 |
0.508 |
|
| 2016 |
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, ... ... Pang PS, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. The Lancet. Infectious Diseases. PMID 26907736 DOI: 10.1016/S1473-3099(16)00052-9 |
0.497 |
|
| 2016 |
Welzel TM, Reddy KR, Flamm SL, Denning J, Lin M, Hyland R, Pang PS, McHutchison JG, Charlton M, Everson GT, Zeuzem S, Afdhal N. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antiviral Therapy. PMID 26891418 DOI: 10.3851/Imp3037 |
0.555 |
|
| 2016 |
Chuang WL, Chien RN, Peng CY, Chang TT, Lo GH, Sheen IS, Wang HY, Chen JJ, Yang JC, Knox SJ, Gao B, Garrison KL, Mo H, Pang PS, Hsu YC, et al. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. Journal of Gastroenterology and Hepatology. PMID 26841930 DOI: 10.1111/Jgh.13305 |
0.512 |
|
| 2016 |
Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, Pang PS, Samuel D, Loustaud-Ratti V. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. The Lancet. Infectious Diseases. PMID 26803446 DOI: 10.1016/S1473-3099(15)00529-0 |
0.542 |
|
| 2015 |
Wilder JM, Jeffers LJ, Ravendhran N, Shiffman ML, Poulos J, Sulkowski MS, Gitlin N, Workowski K, Zhu Y, Yang JC, Pang PS, McHutchison JG, Muir AJ, Howell C, Kowdley K, et al. Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data. Hepatology (Baltimore, Md.). PMID 26547499 DOI: 10.1002/Hep.28334 |
0.473 |
|
| 2015 |
Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, et al. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 26521268 DOI: 10.1093/Cid/Civ874 |
0.537 |
|
| 2015 |
Simon TG, Kim AY, Stamm LM, Liu L, Mo H, Doehle B, Pang PS, Brainard DM, McHutchison JG, Gustafson J, Lauer GM, Chung RT. The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antiviral Therapy. PMID 26440471 DOI: 10.3851/Imp2997 |
0.539 |
|
| 2015 |
Kowdley KV, An D, Pang PS, Wyles D. Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection. Open Forum Infectious Diseases. 2: ofv056. PMID 26380348 DOI: 10.1093/Ofid/Ofv056 |
0.551 |
|
| 2015 |
Stedman CA, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia : the Official Journal of the World Federation of Hemophilia. PMID 26315711 DOI: 10.1111/hae.12791 |
0.386 |
|
| 2015 |
Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, Stedman CA. Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection. Gastroenterology. 149: 1454-1461.e1. PMID 26261007 DOI: 10.1053/J.Gastro.2015.07.063 |
0.546 |
|
| 2015 |
Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, ... ... Pang PS, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England Journal of Medicine. 373: 705-13. PMID 26196665 DOI: 10.1056/Nejmoa1501315 |
0.513 |
|
| 2015 |
Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. The Lancet. Infectious Diseases. PMID 26187031 DOI: 10.1016/S1473-3099(15)00157-7 |
0.555 |
|
| 2015 |
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, ... ... Pang PS, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology. PMID 25985734 DOI: 10.1053/J.Gastro.2015.05.010 |
0.511 |
|
| 2015 |
Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology (Baltimore, Md.). 62: 25-30. PMID 25963890 DOI: 10.1002/Hep.27890 |
0.462 |
|
| 2015 |
Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, ... ... Pang PS, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. The Lancet. Infectious Diseases. 15: 645-53. PMID 25863559 DOI: 10.1016/S1473-3099(15)70099-X |
0.479 |
|
| 2015 |
Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology (Baltimore, Md.). 62: 79-86. PMID 25846144 DOI: 10.1002/Hep.27826 |
0.504 |
|
| 2015 |
Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, Pang PS, Zhu Y, McHutchison JG, Flamm S, Lawitz E. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology (Baltimore, Md.). 61: 1793-7. PMID 25846014 DOI: 10.1002/Hep.27814 |
0.507 |
|
| 2015 |
Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). The Lancet. Infectious Diseases. 15: 397-404. PMID 25773757 DOI: 10.1016/S1473-3099(15)70050-2 |
0.544 |
|
| 2015 |
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, ... ... Pang PS, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Jama. 313: 1232-9. PMID 25706232 DOI: 10.1001/Jama.2015.1373 |
0.485 |
|
| 2015 |
Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, ... ... Pang PS, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 385: 1107-13. PMID 25591505 DOI: 10.1016/S0140-6736(14)61228-9 |
0.466 |
|
| 2015 |
Cho NJ, Lee C, Pang PS, Pham EA, Fram B, Nguyen K, Xiong A, Sklan EH, Elazar M, Koytak ES, Kersten C, Kanazawa KK, Frank CW, Glenn JS. Phosphatidylinositol 4,5-bisphosphate is an HCV NS5A ligand and mediates replication of the viral genome. Gastroenterology. 148: 616-25. PMID 25479136 DOI: 10.1053/J.Gastro.2014.11.043 |
0.474 |
|
| 2015 |
Naggie S, Cooper C, Sulkowski M, Kwo P, Kowdley K, Naik S, Natha M, Stamm L, Pang PS. Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-infected Patients Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv133.1224 |
0.507 |
|
| 2015 |
Doyle E, Custodio J, Pang PS, Das M, Cao H, Ma G, Mathias A, Zack J. Lack of Drug Interactions Between Boosted and Unboosted Tenofovir Alafenamide-Based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the Anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv131.80 |
0.449 |
|
| 2015 |
Lim Y, Chuang W, Ahn S, Peng C, Paik S, Chien R, Chu C, Yang J, Mo H, Gao B, Pang P, Knox S, McHutchison J, Lee Y, Chang T, et al. P0857 : 98% SVR12 in Korean and Taiwanese patients with chronic genotype 1 HCV infection receiving 12 weeks of ledipasvir/sofosbuvir: Results from an international, multicenter phase 3 study Journal of Hepatology. 62: S661-S662. DOI: 10.1016/S0168-8278(15)31059-X |
0.496 |
|
| 2015 |
Burton JR, O’Leary JG, Helmke S, Herman A, Cookson M, Lauriski S, Trotter JF, Denning J, Pang P, McHutchison J, Curry MP, Everson GT. P0814 : Hepatic improvement in response to ledipasvir/sofosbuvir/ribavirin as measured by the hepquant® (HQ)-shunt test in liver transplant (LT) recipients with allograft fibrosis or cirrhosis and non-LT patients with decompensated cirrhosis Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)31017-5 |
0.323 |
|
| 2015 |
Omata M, Takehara T, Yokosuka O, Sakamoto N, Korenagai M, Mochizuki H, Nakane K, Enomoto H, Yanase M, Toyoda H, Ikeda F, Genda T, Umemura T, Yatsuhashi H, Ide T, ... ... Pang PS, et al. P0786 : 100% SVR12 with ledipasvir/sofosbuvir±ribavirin for 12 weeks in Japanese patients with chronic genotype 1 hepatitis C virus who previously failed therapy with protease inhibitor + pegylated interferonα + ribavirin Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30989-2 |
0.465 |
|
| 2015 |
Forns X, Mutimer D, Manns M, Reddy KR, Everson GT, Flamm SL, Denning J, Arterburn S, Brandt-Sarif T, Pang PS, McHutchison JG, Afdhal N, Charlton M, Samuel D, Gane E. P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30982-X |
0.342 |
|
| 2015 |
Samuel D, Manns M, Forns X, Flamm SL, Reddy KR, Denning J, Arterburn S, Brandt-Sarif T, Pang PS, McHutchison JG, Afdhal N, Charlton M, Gane E, Mutimer D, Everson GT. P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30977-6 |
0.441 |
|
| 2015 |
Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, Martin R, Zeuzem S, Lawitz E, Hyland R, Pang PS, Knox S, Gane E, Reddy R, Afdhal N, Mizokami M, Omata M, et al. P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30976-4 |
0.441 |
|
| 2015 |
Abergel A, Loustaud-Ratti V, Metivier S, Jiang D, Kersey K, Knox SJ, Pang PS, Samuel D, Asselah T. O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30070-2 |
0.487 |
|
| 2015 |
Lawitz E, Flamm S, Yang JC, Pang PS, Zhu Y, Svarovskaia E, McHutchison JG, Wyles D, Pockros P. O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30012-X |
0.315 |
|
| 2015 |
Manns M, Forns X, Samuel D, Denning J, Arterburn S, Brandt-Sarif T, Dvory-Sobol H, Pang PS, McHutchison JG, Gane E, Mutimer D. G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial Journal of Hepatology. 62. DOI: 10.1016/S0168-8278(15)30003-9 |
0.397 |
|
| 2015 |
Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, Mchutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, et al. Safety and Tolerability Of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Phase III ION Trials Hepatology. 62: 25-30. DOI: 10.1002/hep.27890 |
0.319 |
|
| 2014 |
Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, Silk R, Townsend K, Pang PS, Subramanian GM, McHutchison JG, Fauci AS, Masur H, Kottilil S. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Annals of Internal Medicine. 161: 634-8. PMID 25364884 DOI: 10.7326/M14-1211 |
0.534 |
|
| 2014 |
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, ... ... Pang PS, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. The New England Journal of Medicine. 370: 1889-98. PMID 24725239 DOI: 10.1056/Nejmoa1402454 |
0.529 |
|
| 2014 |
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, ... ... Pang PS, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. The New England Journal of Medicine. 370: 1483-93. PMID 24725238 DOI: 10.1056/Nejmoa1316366 |
0.526 |
|
| 2014 |
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, ... ... Pang PS, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. The New England Journal of Medicine. 370: 1879-88. PMID 24720702 DOI: 10.1056/Nejmoa1402355 |
0.542 |
|
| 2014 |
Nelson D, Yoshida EM, Paulson MS, Hengen PN, Ge D, Kanwar B, McNally J, Pang PS, Subramanian GM, McHutchison JG, Urbanek P, Lawitz E, Urban TJ. Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor. Antiviral Therapy. 19: 679-86. PMID 24503447 DOI: 10.3851/Imp2747 |
0.504 |
|
| 2014 |
Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, et al. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology (Baltimore, Md.). 60: 56-64. PMID 24501005 DOI: 10.1002/hep.27053 |
0.426 |
|
| 2014 |
Guedj J, Pang PS, Denning J, Rodriguez-Torres M, Lawitz E, Symonds W, Perelson AS. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antiviral Therapy. 19: 211-20. PMID 24464551 DOI: 10.3851/IMP2733 |
0.438 |
|
| 2014 |
Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 146: 736-743.e1. PMID 24262278 DOI: 10.1053/J.Gastro.2013.11.007 |
0.488 |
|
| 2014 |
Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet (London, England). 383: 515-23. PMID 24209977 DOI: 10.1016/S0140-6736(13)62121-2 |
0.53 |
|
| 2014 |
Sulkowski M, Kowdley K, Ruane P, Hawkins T, Elion R, Workowski K, Mills A, Subramanian M, Ding X, Seyedkazemi S, Hyland RH, Yang JC, Pang PS, Mchutchison JG, Afdhal N, et al. 1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis Open Forum Infectious Diseases. 1. DOI: 10.1093/Ofid/Ofu051.111 |
0.47 |
|
| 2014 |
Afdhal N, Reddy RK, Pockros P, Bisceglie AMD, Arora S, Yang JC, Dvory-Sobol H, Zhu Y, Pang PS, Symonds WT, McHutchison JG, Sulkowski MS, Kwo P. O109 All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With Or Without Ribavirin For 12 Or 24 Weeks In Treatment-Experienced Genotype 1 Hcv-Infected Patients: The Phase 3 Ion-2 Study Journal of Hepatology. 60. DOI: 10.1016/S0168-8278(14)60111-2 |
0.464 |
|
| 2014 |
Gane EJ, Hyland RH, An D, Pang PS, Symonds WT, Mchutchison JG, Stedman CA. O6 Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe And Effective In Difficult-To-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, And Genotype-1 Patients With Prior Sofosbuvir Treatment Experience Journal of Hepatology. 60. DOI: 10.1016/S0168-8278(14)60008-8 |
0.403 |
|
| 2012 |
Dvory-Sobol H, Wong KA, Ku KS, Bae A, Lawitz EJ, Pang PS, Harris J, Miller MD, Mo H. Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients. Antimicrobial Agents and Chemotherapy. 56: 5289-95. PMID 22869562 DOI: 10.1128/AAC.00780-12 |
0.399 |
|
| 2012 |
Pang PS, Pham EA, Elazar M, Patel SG, Eckart MR, Glenn JS. Structural map of a microRNA-122: hepatitis C virus complex. Journal of Virology. 86: 1250-4. PMID 22072754 DOI: 10.1128/Jvi.06367-11 |
0.432 |
|
| 2011 |
Pang PS, Elazar M, Pham EA, Glenn JS. Simplified RNA secondary structure mapping by automation of SHAPE data analysis. Nucleic Acids Research. 39: e151. PMID 21965531 DOI: 10.1093/Nar/Gkr773 |
0.437 |
|
| 2010 |
Dvory-Sobol H, Pang PS, Glenn JS. The Future of HCV Therapy: NS4B as an Antiviral Target. Viruses. 2: 2481-92. PMID 21157574 DOI: 10.3390/V2112481 |
0.45 |
|
| 2009 |
Pang PS, Kamal A, Glenn JS. The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 15: 1126-32. PMID 19718638 DOI: 10.1002/Lt.21835 |
0.405 |
|
| 2009 |
Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. Plos One. 4: e6579. PMID 19668364 DOI: 10.1371/Journal.Pone.0006579 |
0.518 |
|
| 2009 |
Sklan EH, Charuworn P, Pang PS, Glenn JS. Mechanisms of HCV survival in the host. Nature Reviews. Gastroenterology & Hepatology. 6: 217-27. PMID 19347013 DOI: 10.1038/Nrgastro.2009.32 |
0.308 |
|
| 2008 |
Planet P, Pang P, Kolokotronis S, Glenn J. Evolution of Interferon Therapy Resistance in Hepatitis C Virus International Journal of Infectious Diseases. 12: e429-e430. DOI: 10.1016/J.Ijid.2008.05.1248 |
0.368 |
|
| 2005 |
Pang PS, Jankowsky E, Wadley LM, Pyle AM. Prediction of functional tertiary interactions and intermolecular interfaces from primary sequence data. Journal of Experimental Zoology. Part B, Molecular and Developmental Evolution. 304: 50-63. PMID 15595717 DOI: 10.1002/Jez.B.21024 |
0.556 |
|
| 2002 |
Pang PS, Jankowsky E, Planet PJ, Pyle AM. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. The Embo Journal. 21: 1168-76. PMID 11867545 DOI: 10.1093/Emboj/21.5.1168 |
0.629 |
|
| Show low-probability matches. |